1077TiP TAK-500 as a single agent and in combination with pembrolizumab in patients (pts) with advanced solid tumors: Rationale and design of a phase I/II study
Singh, H., Diamond, J.R., Henry, J.T., Olszanski, A.J., Rasco, D., Patel, S.P., Gregory, R., Appleman, V.A., Gibbs, J.P., Zhang, W., Wang, C.I., Parent, A.A., Chung, V.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
A Phase 1 Study of TAK-676, a Novel STING Agonist, Plus Pembrolizumab Following Radiation Therapy in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC), Triple-Negative Breast Cancer (TNBC), or Squamous-Cell Carcinoma of the Head and Neck (SCCHN)
Gerber, N.K., Chmura, S.J., Luke, J.J., Shiao, S.L., Basho, R., Iams, W.T., Page, D.B., Li, C., Gregory, R.C., Shaw, M.H., Horn, K.H., Gibbs, J., Appleman, V.A., Berger, A., Abu-Yousif, A.O., Lineberry, N.B., Stumpo, K.F., Elfiky, A., Cooper, B.
Published in International journal of radiation oncology, biology, physics (01.11.2022)
Published in International journal of radiation oncology, biology, physics (01.11.2022)
Get full text
Journal Article